There is substantial evidence that the detection of T cells specific for the proteins ESAT-6 and CFP-10 using the ex vivo enzyme-linked immunospot technique is a marked improvement on the existing tuberculin skin test (TST). This new technique, which detects γ-interferon-producing T cells, is now available as the commercial assay, T-Spot™.TB.
Introduction
Approximately one-third of the world's population is infected with Mycobacterium tuberculosis, which is one of the major causes of morbidity and mortality throughout the world. The 2006 World Health Organization (WHO) report indicated that 8.9 million new cases of tuberculosis were recorded in 2004, 3.9 million of which were in smear-positive patients, which is the highest risk group for transmitting the disease; and 1.7 million people were reported to have died from the infection. 1, 2 Of the individuals infected with M. tuberculosis, 10% are known to develop active infection at some period in their lives. 3 As approximately one-third of the world's population is infected, it is obvious that there is a huge risk of new cases appearing. The basis of the tuberculosis control strategy used in countries with low endemic levels of tuberculosis involves the diagnosis and treatment of latent tuberculosis infection (LTBI). In countries with high endemic levels, T Ozekinci, E Ozbek, Y Celik Comparison of tuberculin skin test and T-Spot™.TB greater priority is given to the diagnosis and treatment of active tuberculosis; testing for LTBI is usually done only in certain high-risk groups, such as children, household contacts, and individuals with human immunodeficiency virus (HIV) infection. 4 Until recently the tuberculin skin test (TST) was the only test used for the diagnosis of LTBI. In practice, however, there are difficulties in its application, such as the requirement for a return visit by the patient, and variation in the evaluation and interpretation of the result. Furthermore, false positive results can occur as a result of previous Bacille Calmette-Guérin (BCG) vaccinations and non-tuberculosis mycobacterial infections. 4 No new methods of LTBI diagnosis have been developed, however, for about a century. As the humoral immune response to LTBI is generally insufficient, we investigated antigens that may activate the cellular immune response. By investigating the genomes of M. tuberculosis H37RV, M. bovis and BCG, 16 different genome regions have been defined and these have been termed 'regions of difference' (RD). Of these, RD1 was lost in the year 1921 during the passages carried out to produce the BCG vaccination strain; this region does not exist in BCG vaccines or in environmental mycobacteria. Promising results have been reported with the proteins ESAT-6 and CFP-10 RD, which are encoded by RD1 and are absent from BCG vaccines and most non-tuberculosis mycobacteria but are present in M. tuberculosis. 5 -7 In the commercial T-Spot™.TB test, peripheral blood mononuclear cells (PBMCs), obtained by an appropriate method from the patient's blood, are stimulated in microwells with the proteins ESAT-6 and CFP-10, and the interferon (IFN) response is measured by the enzyme-linked immunospot (ELISpot) assay. The aim of the present study was to compare the T-Spot™.TB test with the TST and to evaluate the feasibility of using the T-Spot™.TB test in LTBI patients, in culturenegative active tuberculosis patients, in house contacts, and in tuberculosis clinic and laboratory personnel.
Subjects and methods
The study was performed in the research laboratories of the Faculty of Medicine Department of Microbiology at the University of Dicle between 1 January 2006 and 30 June 2006. We included in the study smear-or culture-positive patients with lung tuberculosis who were hospitalized in the Chest Diseases and Tuberculosis Clinic of the Faculty of Medicine, University of Dicle and at the Tuberculosis Clinic of Diyarbakır Chest Diseases Hospital, individuals exposed to these patients in the domestic setting, personnel working in the tuberculosis clinic and laboratory and, as the control group, individuals with no history of contact with tuberculosis.
STUDY GROUPS
The subjects were divided into four groups. Group 1 consisted of patients who had been found to be smear-or culture-positive in the previous 4 weeks and who were not able to receive treatment or who had received treatment for less than 2 weeks. Group 2 consisted of house contacts, i.e. subjects who had been living for the previous year in the same house as those in Group 1. Group 3 consisted of individuals who had been working in the tuberculosis clinic or laboratory for more than 6 months and who were at risk of infection. Group 4 comprised individuals with no history of exposure to tuberculosis.
All participants were questioned for diseases that can cause immunosuppression. As Turkey has a low prevalence of HIV, routine HIV tests were not T Ozekinci, E Ozbek, Y Celik Comparison of tuberculin skin test and T-Spot™.TB performed. Participants were questioned about their BCG vaccination history and we looked for vaccination scars.
TUBERCULIN SKIN TEST
For the TST we used 5 IU purified protein derivative (PPD) (Tuberculin PPD RT 23 SSI, Statens Serum Institut, Copenhagen, Denmark; tuberculin activity, 5 PPD-S). PPD was injected intradermally on the volar surface of an arm of all the individuals included in the study, and assessments were made after 48 -72 h. We evaluated the TST according to the criteria used in Turkey (determined by the Ministry of Health of the Turkish Republic), which are based on vaccination status. In people who had a previous BCG vaccination, an induration size of 15 mm was taken as the cut-off value; in those without a previous BCG vaccination 10 mm was taken as the cut-off value. 8
T-SPOT™.TB TEST
The T-Spot™.TB assay kit (Oxford Immunotec, Abingdon, UK) was used according to the manufacturer's recommendations. Heparinized blood (10 ml) was taken from each patient by venipuncture, transported to the testing laboratory and PBMCs were separated within 2 -4 h. The control wells contained 50 µl of Gibco™ AIM-V (Invitrogen, Carlsbad, CA, USA) cell culture medium (negative control) or phytohaemaggutinin (positive control). The test wells contained 50 µl CFP-10 protein (panel A) and 50 µl ESAT-6 protein (panel B). A mixture of 250 000 PBMCs in 100 µl carrier solution (Aim-V serum) was prepared from the blood samples, as recommended by the manufacturer of the T-Spot™.TB assay kit, and was added to the negative and positive control wells and to both test wells (panels A and B). The microtitre plates were then incubated at 37 ± 1 ºC under 5% carbon dioxide for 16 -20 h. Following incubation, the plates were washed four times with 200 µl phosphate-buffered saline (PBS, 1/200 dilution, pH 7.4) and 50 µl of study conjugate (mixture conjugated with alkaline phosphatase and then concentrated) was then added to each well, and the plates were incubated for a further 60 min at 4 ºC. The microtitre plates were then washed four times with 200 µl PBS and 50 µl of BCIP/ NBT (5-bromo-4-chloro-3-indolyl phosphate/ nitroblue tetrazolium) substrate solution was added to all wells. Incubation was then performed for 7 min at room temperature and the wells were washed with distilled water. The microtitre plates were left to dry in a dark, well-ventilated place at 37 ºC. Coloured spots in the wells were counted under a microscope.
STATISTICAL ANALYSIS
The accordance (agreement) between the two tests was analysed using the kappa coefficient. The χ 2 test was used to analyse the relationship between two tests by 2 x 2 contigency table. Statistical analyses were performed using SPSS ® for Windows ® version 15.0 (SSPS Inc., Chicago, IL, USA). Standard errors and confidence intervals of the kappa coefficient were computed. P value of < 0.05 was considered to indicate statistical significance.
Results
A total of 178 subjects (120 vaccinated, 58 not vaccinated) were included in the study.
Group 1 consisted of 28 smear-positive patients with active tuberculosis. Their ages ranged from 18 to 63 years (mean 41). The T-Spot™.TB test was positive in 26 (92.8%) patients and 22 of these were positive for the TST. The T-Spot™.TB test was negative in two (7.2%) patients and one of these patients Accordance (agreement) between the two tests in groups 1 -3 is shown in Table 1 . The highest total accordance (positive plus negative agreement) occurred in group 1 (85.7%; κ = 0.681, P < 0.001). Total accordance was lower, though still significant, in group 3 (63.6%; κ = 0.305, P = 0.006); however in group 2 total accordance was lower than for the other groups and not significant (53.6%, κ = 0.011, P > 0.05).
Evaluation of the two at-risk groups (groups 2 and 3) based on their BCG vaccination status ( Group 1, patients with active lung tuberculosis; they had been found to be smear-or culture-positive in the previous 4 weeks and were either unable to receive treatment or had been treated for < 2 weeks. Group 2, house contacts, i.e. subjects who had been living in the same house as the group 1 participants for the previous 1 year. Group 3, subjects who had worked in a tuberculosis clinic or laboratory for > 6 months.
TABLE 1: Comparison of accordance between the T-Spot™.TB test with the tuberculin skin test in the various groups studied
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been vaccinated (20.0%). On the other hand, negative accordance was higher in those who had been vaccinated (43.5%) than in those who had not been vaccinated (36.7%). Total accordance was higher and significant in the vaccinated subjects (59.8%; κ = 0.237, P = 0.005) compared with the nonvaccinated subjects where it was relatively weak and non-significant (56.7%; κ = 0.133, P > 0.05).
Discussion
In populations in which tuberculosis is widespread, a significant proportion of tuberculosis control programmes include the diagnosis and treatment of infected individuals. The aim of the TST and chemotherapy is to prevent progression of the low-incidence LTBI into prominent tuberculosis infection.
The sensitivity and specificity of the TST, which has been the sole diagnostic method to date, are not ideal for the detection of tuberculosis infection. Difficulties in its use include the requirement for a return visit from the patient, variability in the application and evaluation of test results, and differences in interpretation. 9, 10 Owing to the occurrence of false positive results originating from previous BCG vaccination and from non-tuberculosis mycobacterial infections, antigens that do not cross-react with BCG have been looked at and, in this regard, the ESAT-6 and CFP-10 proteins represent an important advance. 5 -7 The T-Spot™.TB test that we used in our study is based on the detection of CD4 T cells secreting specific IFN-γ against ESAT-6 and CFP-10 in the blood of individuals infected with tuberculosis bacilli. The most important problem in studies comparing the T-Spot™.TB test and the TST is the lack of a standard diagnostic method. For this reason, in our statistical analysis we compared the two methods in subjects with similar epidemiological features.
In a previous study, Lee et al. 11 prospectively compared two blood tests based on the ex vivo cellular IFN-γ response (Quantiferon ® -TB Gold and T-Spot™.TB) and the TST in 218 individuals, 87 of whom had active tuberculosis and 131 who were at risk of tuberculosis. The sensitivity of the T-Spot™.TB test (95.4%) was higher than that of the Quantiferon ® -TB Gold test (70.1%); the sensitivity of the TST, using an induration response of ≥ 10 mm as the cutoff point, was 66.7% (P < 0.005 for T-Spot™.TB compared with each of the other comparator tests). Although the specificity of the Quantiferon ® -TB Gold test was higher than that of the T-Spot™.TB test (91.6% versus 84.7%), this difference was not statistically significant. Despite some differences in the performance of the two tests in measuring IFN-γ, both were found to be superior to the TST in the detection of M. tuberculosis infection.
In another study, Diel et al. 12 compared TST with ELISpot during an M. tuberculosis epidemic at a police academy in Germany. Thirty-six close contacts and 333 casual contacts were investigated. When the ELISpot test was applied to TST-positive (induration response ≥ 5 mm) subjects, positivity was detected in 19 (53%) of the 36 close contacts and in 52 (16%) of the 333 casual contacts. In total, the ELISpot test was positive for 56 (78.9%) of the 71 TST-positive cases and for 27 (9.1%) of the 298 TSTnegative cases, so the accordance between TST and ELISpot was weak. In contrast, when an induration diameter of ≥10 mm was considered positive in non-vaccinated cases, accordance between the two tests was strong. In BCG-vaccinated subjects, the authors found that ELISpot was a better indicator of LTBI than the TST test.
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Ewer et al. 13 have performed screening with the TST and an M. tuberculosis ELISpot test in 535 students at a school in England, where there was a contamination risk originating from a single case of M. tuberculosis infection. Although a high degree of accordance was detected between the two tests, the TST was significantly more likely to be positive in BCG-vaccinated individuals than in non-vaccinated individuals, whereas no significant association was detected between ELISpot positivity and BCG vaccination. The ELISpot test was found to be superior to the TST in terms of detecting contact with M. tuberculosis.
Meier et al. 7 have compared the T-Spot™.TB test with the TST method in 90 randomly chosen cases with known or suspected tuberculosis. The T-Spot™.TB test was positive in 70 (97.2%) of the 72 patients with lung or non-lung tuberculosis. Of the 59 patients who were tested with both TST and T-Spot™.TB, 45 displayed lung and non-lung tuberculosis; whereas the T-Spot™.TB test was positive in all of these cases (100%), TST was positive in only 40 (89%). The T-Spot™.TB test was also shown to have a 97% diagnostic sensitivity. The authors concluded that T-Spot™.TB was a sensitive test in detecting tuberculosis infection and that it had the additional advantage of being able to detect tuberculosis in locations where there is a low incidence of the disease.
Lalvani et al. 14 found an M. tuberculosis ELISpot test to be positive in 45 of 47 bacteriologically confirmed tuberculosis patients, giving a sensitivity of 96%. In the same study, although 36 (77%) of the 47 subjects in the control group -individuals with non-tuberculosis diseases -were vaccinated with BCG, only four responded positively to the ELISpot test, and only one of those who responded positively was found to be BCG-positive. Thus, the specificity of the test was found to be 92%. In the same study, the TST was applied to 26 patients with tuberculosis and only 18 (69%) of these were positive. Of these 26 patients, 22 (85%) responded positively to the ELISpot test. Thus, a statistically very significant difference in sensitivity was found between the two methods.
Tests based on the IFN-γ response provide fast detection of M. tuberculosis in patients with active tuberculosis and in asymptomatic individuals with a high risk of latent infection; furthermore, such tests successfully differentiate BCG vaccination from M. tuberculosis infection. This makes tuberculosis control in endemic regions easier. In a study done in Zambia, 15 the sensitivity of the ELISpoT test for LTBI detection was 90% in HIV-positive patients and 100% in HIV-negative patients, and the ELISpot test was more sensitive and specific than the TST in the detection of LTBI in immune-suppressed patients.
Liebeshuetz et al. 16 have studied an M. tuberculosis ELISpot test and the TST in 293 children with suspected tuberculosis living in a region of Africa with high HIV prevalence. They found that the sensitivity of the ELISpot test (83%) was significantly higher than that of the TST (63%).
Zellweger et al. 17 compared the TST and the T-Spot™.TB test in individuals living in a residential institution where an individual with smear-positive lung tuberculosis was also living. They found no correlation between the TST result and the degree of contact with the tuberculosis patient, but there was a significant correlation between the T-Spot™.TB test and the degree of contact. Whereas the TST was significantly more often positive in contacts who had been vaccinated with BCG than in nonvaccinated contacts, vaccination did not T Ozekinci, E Ozbek, Y Celik Comparison of tuberculin skin test and T-Spot™.TB affect the T-Spot™.TB results (52% versus 0%).
Hill et al. 18 have compared the TST and ELISpot tests in children who were exposed to M. tuberculosis in Gambia. They found 83% accordance between the tests and reported that discordance was not significant. The ELISpot test was slightly more sensitive than the TST and was not affected by BCG vaccination. The authors suggested that it may be advantageous to use the two tests together when maximum sensitivity is important.
Wrighton-Smith and Zellweger 19 screened for LTBI using different methods in three groups of subjects, and considered the costs of both screening and treatment. They used only the TST in the first group and only the T-Spot™.TB test in the second group; in the third group the TST was used initially and the T-Spot™.TB test was then used in those with a positive TST result. The most costeffective method was found to be that used in the third group.
Doherty et al. 20 followed 24 healthy individuals for 2 years who had previous contact with tuberculosis patients and had no symptoms related to tuberculosis and no radiological or any other findings related to the infection. Of the seven individuals who developed tuberculosis, six (86%) responded positively to ESAT-6 at the beginning of the study; only three (18%) of the remaining 17 were positive (two of these had symptoms but tuberculosis could not be confirmed microbiologically).
In our study, accordance between the TST and T-Spot™.TB tests was highest in the group that comprised patients with active lung tuberculosis; of the groups with lower concordance values (high risk groups), the group of clinic and laboratory personnel showed higher accordance than the house contacts. When these two high risk groups were evaluated in terms of BCG vaccination status, positive accordance was lower in vaccinated than in unvaccinated individuals, while negative accordance was higher in vaccinated than in non-vaccinated individuals. Total accordance was higher in vaccinated than in non-vaccinated individuals, but at a low level of accordance.
We consider that the T-Spot™.TB test is more useful than the TST for the accurate diagnosis of LTBI and in the detection of those who require treatment. The high cost of the T-Spot™.TB test and the need for advanced laboratory facilities and trained personnel seem to be preventing its routine use. However, the TST, which has been used in the detection of LTBI for more than 100 years, is prone to false positive or false negative results as it is a subjective test; furthermore, it requires the tested individuals to be contacted again after 2 -3 days, and reactions may develop as a result of secondary causes, the subject's immune status and previous vaccinations, and nontuberculosis mycobacterial infections.
In view of all these considerations we conclude that, in countries where vaccination is routinely performed, the T-Spot™.TB test can be used with advantage in the diagnosis of LTBI in high-risk groups, either together with the TST and/or for the confirmation of the TST result. There is a need for wide-ranging studies of longer duration, observing the conversion of latent infection to active disease, using new diagnostic tests such as the T-Spot™.TB.
